

**From:** [Modi, Naveen](#)  
**To:** [Trials](#)  
**Cc:** [BioNTech-Moderna-IPR](#); [COVIDPatentPfizer](#); [WH\\_Moderna\\_IPR](#)  
**Subject:** IPR2023-01358, -01359 - Public Version of Final Written Decisions  
**Date:** Wednesday, March 12, 2025 8:44:12 AM  
**Attachments:** [image001.png](#)

---

CAUTION: This email has originated from a source outside of USPTO. PLEASE CONSIDER THE SOURCE before responding, clicking on links, or opening attachments.

Dear Honorable Board:

As ordered in the Board's March 5, 2025 Final Written Decisions, the parties to the above-referenced proceedings have conferred and do not propose any redactions to the Board's Decisions, IPR2023-01358, Paper 86 and IPR2023-01359, Paper 86.

Respectfully submitted,  
Naveen Modi  
Counsel for Petitioner

---

**PAUL**  
**HASTINGS**

**Naveen Modi | Global Co-Chair, Intellectual Property, & Partner, Litigation Department**  
Paul Hastings LLP | 2050 M Street NW, Washington, DC 20036 | Direct: +1.202.551.1990 | Main:  
+1.202.551.1700 | Fax: +1.202.551.0490 | [naveenmodi@paulhastings.com](mailto:naveenmodi@paulhastings.com) | [www.paulhastings.com](http://www.paulhastings.com)

\*\*\*\*\*  
This message is sent by a law firm and may contain information that is privileged or confidential. If you received this transmission in error, please notify the sender by reply e-mail and delete the message and any attachments. If you reply to this message, Paul Hastings may collect personal information including your name, business name and other contact details, and IP address. For more information about Paul Hastings' information collection, privacy and security principles please click [HERE](#). If you have any questions, please contact [Privacy@paulhastings.com](mailto:Privacy@paulhastings.com).